Table of Contents Author Guidelines Submit a Manuscript
International Journal of Rheumatology
Volume 2011, Article ID 275617, 6 pages
http://dx.doi.org/10.1155/2011/275617
Research Article

Basal Activation of Type I Interferons (Alpha2 and Beta) and OAS Genes: Insights into Differential Expression Profiles of Interferon System Components in Systemic Sclerosis

1Laboratório de Vírus, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Avenue Antônio Carlos 6627, Pampulha 31270-901 Belo Horizonte, MG, Brazil
2Hospital das Clínicas, Universidade Federal de Minas Gerais, Avenue Alfredo Balena 110, Santa Efigênia, 30130-100 Belo Horizonte, MG, Brazil

Received 15 June 2011; Revised 10 August 2011; Accepted 23 August 2011

Academic Editor: Lorinda Chung

Copyright © 2011 Danilo Bretas de Oliveira et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. D. Steen, “Systemic sclerosis,” Rheumatic Disease Clinics of North America, vol. 16, no. 3, pp. 641–654, 1990. View at Google Scholar · View at Scopus
  2. R. D. Sontheimer, “Skin manifestations of systemic autoimmune connective tissue disease: diagnostics and therapeutics,” Best Practice and Research: Clinical Rheumatology, vol. 18, no. 3, pp. 429–462, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. C. P. Denton and C. M. Black, “Scleroderma—clinical and pathological advances,” Best Practice and Research: Clinical Rheumatology, vol. 18, no. 3, pp. 271–290, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Chizzolini, N. C. Brembilla, E. Montanari, and M. E. Truchetet, “Fibrosis and immune dysregulation in systemic sclerosis,” Autoimmunity Reviews, vol. 10, no. 5, pp. 276–281, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. D. J. Abraham and J. Varga, “Scleroderma: from cell and molecular mechanisms to disease models,” Trends in Immunology, vol. 26, no. 11, pp. 587–595, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. N. R. Rose and N. Leskovsek, “Scleroderma: immunopathogenesis and treatment,” Immunology Today, vol. 19, no. 11, pp. 499–501, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Tahara, A. Kojima, T. Hirokawa et al., “Systemic sclerosis after interferon alphacon-1 therapy for hepatitis C,” Internal Medicine, vol. 46, no. 8, pp. 473–476, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Assassi, M. D. Mayes, F. C. Arnett et al., “Systemic sclerosis and lupus: points in an interferon-mediated continuum,” Arthritis and Rheumatism, vol. 62, no. 2, pp. 589–598, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Allanore, D. Borderie, P. Hilliquin et al., “Low levels of nitric oxide (NO) in systemic sclerosis: inducible NO synthase production is decreased in cultured peripheral blood monocyte/macrophage cells,” Rheumatology, vol. 40, no. 10, pp. 1089–1096, 2001. View at Google Scholar · View at Scopus
  10. L. F. L. Coelho, J. G. de Oliveira, and E. G. Kroon, “Interferons and scleroderma-A new clue to understanding the pathogenesis of scleroderma?” Immunology Letters, vol. 118, no. 2, pp. 110–115, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. L. I. Sakkas, C. Tourtellotte, S. Berney, A. R. Myers, and C. D. Platsoucas, “Increased levels of alternatively spliced interleukin 4 (IL-4δ2) transcripts in peripheral blood mononuclear cells from patients with systemic sclerosis,” Clinical and Diagnostic Laboratory Immunology, vol. 6, no. 5, pp. 660–664, 1999. View at Google Scholar · View at Scopus
  12. M. Molteni, S. Della Bella, B. Mascagni et al., “Increased interferon-gamma (IFN-γ) levels produced in vitro by alloactivated T lymphocytes in systemic sclerosis and Raynaud's phenomenon,” Clinical and Experimental Immunology, vol. 116, no. 1, pp. 164–168, 1999. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Yamamoto, I. Katayama, and K. Nishioka, “Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis,” Journal of Rheumatology, vol. 25, no. 2, pp. 314–317, 1998. View at Google Scholar · View at Scopus
  14. H. Ihn, S. Sato, M. Fujimoto et al., “Circulating intercellular adhesion molecule-1 in the sera of patients with systemic sclerosis: enhancement by inflammatory cytokines,” British Journal of Rheumatology, vol. 36, no. 12, pp. 1270–1275, 1997. View at Google Scholar · View at Scopus
  15. G. Valentini, A. Baroni, K. Esposito et al., “Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation,” Journal of Clinical Immunology, vol. 21, no. 3, pp. 210–217, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Kontsek, G. Karayianni-Vasconcelos, and E. Kontseková, “The human interferon system: characterization and classification after discovery of novel members,” Acta Virologica, vol. 47, no. 4, pp. 201–215, 2003. View at Google Scholar · View at Scopus
  17. S. Pestka, C. D. Krause, and M. R. Walter, “Interferons, interferon-like cytokines, and their receptors,” Immunological Reviews, vol. 202, pp. 8–32, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Banchereau and V. Pascual, “Type I interferon in systemic lupus erythematosus and other autoimmune diseases,” Immunity, vol. 25, no. 3, pp. 383–392, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. L. F. L. Coelho, J. G. de Oliveira, D. B. de Oliveira et al., “Increased expression of 2′5′oligoadenylate synthetase and double-stranded RNA dependent protein kinase messenger RNAs on affected skin of systemic sclerosis patients,” Archives of Dermatological Research, vol. 299, no. 5-6, pp. 259–262, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. A. N. Theofilopoulos, R. Baccala, B. Beutler, and D. H. Kono, “Type I interferons (α/β) in immunity and autoimmunity,” Annual Review of Immunology, vol. 23, pp. 307–336, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Hikami, Y. Ehara, M. Hasegawa et al., “Association of IL-10 receptor 2 (IL10RB) SNP with systemic sclerosis,” Biochemical and Biophysical Research Communications, vol. 373, no. 3, pp. 403–407, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. M. K. Crow and K. A. Kirou, “Interferon-induced versus chemokine transcripts as lupus biomarkers,” Arthritis Research and Therapy, vol. 10, no. 6, article 126, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Farina, D. Lafyatis, R. Lemaire, and R. Lafyatis, “A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis,” Arthritis and Rheumatism, vol. 62, no. 2, pp. 580–588, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. F. K. Tan, X. Zhou, M. D. Mayes et al., “Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients,” Rheumatology, vol. 45, no. 6, pp. 694–702, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. R. B. Christmann, E. Hayes, S. Pendergrass et al., “Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension,” Arthritis and Rheumatism, vol. 63, no. 6, pp. 1718–1728, 2011. View at Publisher · View at Google Scholar
  26. A. Böyum, “Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 97, pp. 77–89, 1968. View at Google Scholar
  27. P. C. P. Ferreira, M. L. P. Peixoto, M. A. V. Silva, and R. R. Golgher, “Assay of human interferon in Vero cells by several methods,” Journal of Clinical Microbiology, vol. 9, no. 4, pp. 471–475, 1979. View at Google Scholar · View at Scopus
  28. Z. Marijanovic, J. Ragimbeau, J. van der Heyden, G. Uzé, and S. Pellegrini, “Comparable potency of IFNα2 and IFNβ on immediate JAK/STAT activation but differential down-regulation of IFNAR2,” Biochemical Journal, vol. 407, no. 1, pp. 141–151, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. P. I. Osterlund, T. E. Pietila, V. Veckman, S. V. Kotenko, and I. Julkunen, “IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes,” Journal of Immunology, vol. 179, no. 6, pp. 3434–3442, 2007. View at Google Scholar
  30. S. Ye, Q. Guo, J. P. Tang, C. D. Yang, N. Shen, and S. L. Chen, “Could 25-oligoadenylate synthetase isoforms be biomarkers to differentiate between disease flare and infection in lupus patients? A pilot study,” Clinical Rheumatology, vol. 26, no. 2, pp. 186–190, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. M. L. Eloranta, K. Franck-Larsson, T. Lövgren et al., “Type I interferon system activation and association with disease manifestations in systemic sclerosis,” Annals of the Rheumatic Diseases, vol. 69, no. 7, pp. 1396–1402, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Marshak-Rothstein, “Toll-like receptors in systemic autoimmune disease,” Nature Reviews Immunology, vol. 6, no. 11, pp. 823–835, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. S. K. Agarwal, M. Wu, C. K. Livingston et al., “Toll-like receptor 3 upregulation by type I interferon in healthy and scleroderma dermal fibroblasts,” Arthritis Research and Therapy, vol. 13, no. 1, article 3, 2011. View at Google Scholar